Quarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19
- PMID: 35909795
- PMCID: PMC9335027
- DOI: 10.1093/pnasnexus/pgac100
Quarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19
Abstract
Quarantine and serial testing strategies for a disease depend principally on its incubation period and infectiousness profile. In the context of COVID-19, these primary public health tools must be modulated with successive SARS CoV-2 variants of concern that dominate transmission. Our analysis shows that (1) vaccination status of an individual makes little difference to the determination of the appropriate quarantine duration of an infected case, whereas vaccination coverage of the population can have a substantial effect on this duration, (2) successive variants can challenge disease control efforts by their earlier and increased transmission in the disease time course relative to prior variants, and (3) sufficient vaccine boosting of a population substantially aids the suppression of local transmission through frequent serial testing. For instance, with Omicron, increasing immunity through vaccination and boosters-for instance with 100% of the population is fully immunized and at least 24% having received a third dose-can reduce quarantine durations by up to 2 d, as well as substantially aid in the repression of outbreaks through serial testing. Our analysis highlights the paramount importance of maintaining high population immunity, preferably by booster uptake, and the role of quarantine and testing to control the spread of SARS CoV-2.
Keywords: disease time course; omicron; public health; severe acute respiratory syndrome; variants of concern.
© The Author(s) 2022. Published by Oxford University Press on behalf of National Academy of Sciences.
Figures


Similar articles
-
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900. JAMA Netw Open. 2022. PMID: 36018588 Free PMC article.
-
COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups.Infect Dis Ther. 2022 Oct;11(5):2045-2061. doi: 10.1007/s40121-022-00683-z. Epub 2022 Sep 12. Infect Dis Ther. 2022. PMID: 36094720 Free PMC article.
-
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25. Microbiol Spectr. 2022. PMID: 36005765 Free PMC article.
-
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022. Front Immunol. 2022. PMID: 36451833 Free PMC article.
-
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022. Front Public Health. 2022. PMID: 35910897 Free PMC article.
Cited by
-
Economic evaluation of COVID-19 rapid antigen screening programs in the workplace.BMC Med. 2022 Nov 23;20(1):452. doi: 10.1186/s12916-022-02641-5. BMC Med. 2022. PMID: 36424587 Free PMC article.
-
Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study.PLoS Med. 2023 Nov 28;20(11):e1004195. doi: 10.1371/journal.pmed.1004195. eCollection 2023 Nov. PLoS Med. 2023. PMID: 38016000 Free PMC article.
-
Modelling the impact of timelines of testing and isolation on disease control.Infect Dis Model. 2023 Mar;8(1):58-71. doi: 10.1016/j.idm.2022.11.008. Epub 2022 Nov 28. Infect Dis Model. 2023. PMID: 36467718 Free PMC article.
References
-
- Wells CR, et al. . 2022. Comparative analyses of FDA EUA-approved rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation. medRxiv. https://www.medrxiv.org/content/10.1101/2021.08.23.21262499v4, (accessed 2022 Feb 15). 2021.08.23.21262499 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous